Structural Characterization Of GLP-1 Analogues And Formulations Using Microfluidic Modulation Spectroscopy

Glucagon-like peptide-1 (GLP-1) analogues, including semaglutide and liraglutide, are widely used treatments for obesity and type 2 diabetes, valued for their enhanced stability and prolonged half-life. The secondary structure of these peptides is crucial for their receptor binding, stability, and overall efficacy, making detailed structural characterization indispensable during drug development and for quality control.

This application note demonstrates the power of Microfluidic Modulation Spectroscopy (MMS) in precisely quantifying peptide concentrations and identifying subtle structural variations between GLP-1 and its commercial analogues in different buffer systems. Gain a deeper understanding of this cutting-edge biophysical tool by downloading the full application note.